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Abstract
Background: Delirium and dementia share symptoms of cognitive dysfunctions, and mechanisms of neuroinflammation
appear involved in both conditions. Triggering receptor expressed on myeloid cells 2 (TREM2) is linked to dementia and
neurodegenerative disease. It encodes expression of an innate immune receptor in the brain expressed by microglia. The
level of the soluble fragment of TREM2 (sTREM2) is reported to increase in the cerebrospinal fluid (CSF) already in
prodromal and asymptomatic Alzheimer’s disease.
Methods: We analyzed the level of CSF sTREM2 in relation to delirium and dementia. The study included patients
with or without pre-existing dementia who underwent acute hip fracture surgery (n = 120), and some of the
patients developed delirium (n = 65). A medical delirium cohort (n = 26) was also examined. ELISA was used to
determine the level of sTREM2 in CSF.
Results: Delirium was associated with a higher level of CSF sTREM2 only among those without pre-existing dementia
(p = 0.046, n = 15, n = 44), particularly among patients developing delirium after CSF sampling (p = 0.02, n = 7, n = 44).
Between patients with dementia, there was no group difference, but the CSF sTREM2 level increased with waiting time
for surgery (rS = 0.39, p = 0.002, n = 60) and correlated well with the CSF Alzheimer’s disease biomarkers, Aβ42, and t-
tau/p-tau (rS = 0.40, p = 0.002, rS = 0.46, p < 0.001/ rS = 0.49, p < 0.001, n = 60). Among patients with dementia, the level
of Aβ38 and Aβ40 also correlated positively with sTREM2 in CSF (Aβ38MSDrS = 0.44, p = 0.001; Aβ40MSDrS = 0.48, p < 0.
001; Aβ42MSDrS = 0.43, p < 0.001, n = 60).
Conclusion: The findings reinforce the involvement of neuroinflammation in delirium, yet with separate responses in
patients with or without pre-existing dementia. Our findings support the concept of primed microglia in
neurodegenerative disease and central immune activation after a peripheral trauma in such patients. A CSF
biomarker panel of neuroinflammation might be valuable to prevent delirium by identifying patients at risk.
Keywords: Delirium, Dementia, Alzheimer’s disease, CSF biomarkers, Soluble TREM2
Background
Delirium is an acute state of confusion with fluctuating
symptoms of disturbed attention and cognition com-
monly precipitated by stress, such as surgery, in frail pa-
tients [1]. Besides unpleasant while ongoing, a delirium
carries the risk of increased mortality and long-term
sequela of cognitive functions [2]. Although much is un-
known, the delirium pathogenesis is thought to involve
disturbed neurotransmission and/or induced inflamma-
tion with microglial activation [3]. The neuroinflammatory
hypothesis suggest that delirium symptoms arise as central
immunity is activated by initial peripheral inflammation
that convey to the brain [4, 5].
While delirium increases the risk of dementia, demen-
tia is also a delirium risk factor [6–8]. The most com-
mon cause of dementia is Alzheimer’s disease (AD), a
neurodegenerative disorder with pathological hallmarks
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amyloid plaques and neurofibrillary tangles [9]. Already
at a preclinical stage with evident neuropathology is
AD found to increase the risk of delirium [10, 11]. Neu-
roinflammation with microglial activation and astro-
gliosis also plays a role in AD [12]. Thus, delirium and
dementia etiology are intertwined with shared patho-
genic mechanisms such as microglial activation and
other facets of neuroinflammation [13].
Microglia, the resident immune cells of the brain, ex-
press the innate immune receptor triggering receptor
expressed on myeloid cells 2 (TREM2) [14]. Variants of
TREM2 are known as dementia risk factors [15–17]
linking TREM2 to age-related neurodegeneration. The
transmembrane TREM2 receptor undergoes ectodo-
main shedding releasing soluble TREM2 (sTREM2) [18]
(Fig. 1a). In the cerebrospinal fluid (CSF) of AD pa-
tients, sTREM2 is reported increased [19, 20]. An even
higher level is observed at the prodromal mild cognitive
impairment (MCI) stage of AD [21]. Moreover, the level
of CSF sTREM2 correlates positively with the core CSF
biomarkers amyloid beta 1–42 (Aβ42), total-tau (t-tau),
and phosphorylated-tau (p-tau) in asymptomatic pa-
tients, which further suggests an early involvement of
reactive microgliosis [22, 23].
In the present study, we analyzed the CSF sTREM2
level in patients with or without pre-existing dementia.
The patients all suffered a hip fracture with subse-
quent hospital admission and surgery that for some
led to delirium, and we evaluated CSF sTREM2 as a
putative biomarker of delirium. Given the abovemen-
tioned biomarker correlations in AD, we also exam-
ined the relation between CSF sTREM2 and AD core
biomarkers, CSF Aβ42, t-tau, and p-tau. For the poten-
tial influence of a peripheral trauma, we investigated
how the CSF sTREM2 level related to time after hip
fracture. We also included a patient group with delirium
associated with a medical condition to evaluate potential




The hip fracture patients, which were recruited from the
Oslo Orthogeriatric trial (OOT), were admitted to the
Oslo University Hospital Ullevål (OUS, Ullevål) between
September 2009 and January 2012 [24, 25]. Delirium was
assessed using the Confusion Assessment Method
(CAM) [26] by the study physician or a study nurse. De-
lirium was assessed daily preoperatively and until the
fifth postoperative day or in case of delirium until dis-
charge. Pre-fracture dementia status was decided by
consensus and based on the International Classification
of Diseases − 10 (ICD-10) criteria for dementia by an ex-
pert panel as previously described [25].
The hip fracture patients (n = 120) were grouped both
according to delirium and dementia status into either of
the following groups (see Fig. 1a and Table 1)
1. No delirium during the hospital stay (no delirium)
(n = 54)
a. No delirium, and without pre-fracture dementia
(n = 44)
b. No delirium, but pre-fracture dementia (n = 10)
2. Delirium during the hospital stay (delirium) (n = 65)
a. Delirium, but without pre-fracture dementia
(n = 15)
b. Delirium with pre-fracture to dementia (n = 50)
Delirium patients included prevalent delirium (those
that developed delirium preoperatively; n = 41) and in-
cident delirium (postoperative delirium in those free
from delirium before surgery; n = 21). The sub-classifi-
cation of delirium onset was applied for delirium onset
analyses.
Medical delirium cohort
The medical delirium cohort was recruited from a pro-
spective study at the same hospital in which 244 patients
who underwent lumbar puncture (LP) due to suspicion
of acute central nervous system (CNS) infection were in-
cluded. Patients were included between January 2014
and December 2015. The patients included in the
current study (n = 26) were those in which a CNS infec-
tion was ruled out and delirium triggered by another
medical condition was considered the most likely ex-
planation for the acute cognitive symptoms. Pneumonia
and urinary tract infection were the most frequent diag-
noses in this group. All patients had encephalopathy at
the time of the LP. Delirium was assessed either by the
study physician with CAM, or by clinical evaluation of
treating physician in the medical ward. Dementia status
was set from the hospital records. These delirium pa-
tients formed a separate group labeled “medical delir-
ium” afflicted by delirium with another precipitating
factor than the hip fracture patients.
CSF sampling, handling, and storage
In the hip fracture cohort, CSF was collected in connec-
tion with the orthopedic surgery at the onset of spinal
anesthesia before administrating the anesthetic agents.
CSF of patients with medical delirium was obtained dur-
ing the diagnostic lumbar puncture (LP) at a median of
1 day after CNS symptoms developed. CSF was collected
in polypropylene tubes and centrifuged as soon as pos-
sible, and supernatant aliquots were stored in polypro-
pylene tubes at − 80 °C [27].
Henjum et al. Journal of Neuroinflammation          (2018) 15:304 Page 2 of 15
Table 1 Characteristics of the hip fracture and medical delirium patients




All Incident Prevalent Medical
PATIENTS WITHOUT DEMENTIA
N 59 44 15 7 8 17
Age (years) 84 (10) 84 (16) 85 (7) 86 (11) 85 (7) 66 (16)
Gender
Male 17 11 6 3 3 10
Female 42 33 9 4 5 7
Time to surgery (h)* 23 (17) 23 (17) 27 (15) 22 (19) 30 (14) –
CSF sTREM2 ng/ml 7.8 (5.7) 7.4 (5) 11.1(11) 11.6 (5) 7.8 (15) 5.6 (8)
CSF biomarkers
N 57 44 13 5 8
CSF Aβ42 (pg/ml) 446 (367) 479 (414) 283 (224) 283 (232) 295 (253) –
CSF t-tau (pg/ml) 369 (276) 356 (198) 564 (638) 564 (369) 587 (795) –
CSF p-tau (pg/ml) 57(35) 54 (33) 78 (68) 78 (19) 88 (89) –
CSF Aβ42 cut-off (< 530 pg/ml)
Below 37 26 11 4 7 –
Above 20 18 2 1 1 –
CSF p-tau cut-off (≥ 60 pg/ml)
Above 26 17 9 4 5 –
Below 31 27 4 1 3 –
CSF t-tau cut-off (> 350 pg/ml)
Above 32 23 9 5 4 –
Below 25 21 4 – 4 –
PATIENTS WITH DEMENTIA
N 61 10 50 13 33 9
Age (years) 86 (9) 86.5 (17) 85(9) 87 (8) 85 (8) 71(23)
Gender
Male 16 1 15 5 8 6
Female 45 9 35 8 25 3
Time to surgery (h)* 26 (28) 27 (16) 26(31) 18(19) 38 (24) –
CSF sTREM2 ng/ml 7.0 (7.8) 9.2 (16) 7.3 (7) 6.1 (10) 8.5 (8) 6.9(6.7)
CSF biomarkers, N 60 9 50 13 33
CSF Aβ42 (pg/ml) 265 (166) 317 (290) 258 (172) 268 (219) 269 (174) –
CSF t-tau (pg/ml) 408 (379) 441 (503) 408 (366) 385 (293) 407 (329) –
CSF p-tau (pg/ml 55 (41) 58 (57) 55 (35) 55 (47) 55 (31) –
CSF Aβ42 cut-off (< 530 pg/ml)
Below 55 7 47 11 1 –
Above 5 2 3 2 32 –
CSF p-tau cut-off (≥ 60 pg/ml)
Above 24 4 20 5 13 –
Below 36 5 30 8 20 –
CSF t-tau cut-off (> 350 pg/ml)
Above 38 5 33 8 22 –
Below 22 4 17 5 11 –
Data are presented as median and interquartile range (IQR), waiting time for surgery. Aβ42, amyloid beta 1–42; t-tau, total-tau; p-tau, phosphorylated tau;
sTREM2, soluble triggering receptor expressed on myeloid cells
*Time to surgery, hours from hospital admission to surgery (onset of anesthesia) and CSF sampling
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CSF sTREM2 measurements
CSF sTREM2 was assayed by a sensitive TREM2 enzyme-
linked immunosorbent assay (ELISA) as previously de-
scribed [22]. Briefly, plates were incubated with an anti-
humanTREM2 polyclonal capture antibody overnight at
4 °C (AF1828, R&D Systems, Minneapolis, MN, USA) and
TREM2 detected by a mouse anti-human TREM2 mono-
clonal HRP-conjugated antibody (1 h incubation at room
temperature (RT);SEK11084, Sino Biologics, Beijing,
China). Samples were assayed in duplicates (2 h incuba-
tion at RT) with known cohort (hip fracture or medical),
but with the clinical identity unknown to the operator.
Samples with extreme values were assayed again, includ-
ing the same and an increased sample dilution to verify
measurements in the repeated assay. Two internal stand-
ard (CSF) samples were included in each assay to assess
interday variability and used to adjust the medical delir-
ium cohort which was assayed separately from the hip
fracture cohort, with a final CV < 10% across assays.
CSF Aβ, t-tau, and p-tau measurements
CSF levels of t-tau, p-tau, and Aβ42 were quantified
with commercially available ELISAs; Innotest® hTau Ag,
Innotest® phoshoTau (181P), and Innotest® β-amyloid
1–42 as previously described [28–30] (Fujirebio Europe,
Gent, Belgium). CSF Aβ peptide levels were determined
with CSF Aβ1–38 (Aβ38), Aβ1–40 (Aβ40), and Aβ1–42
(Aβ42) MSD Triplex assay (Meso Scale Discovery,
Rockwilly, MA, USA). All these analyses were per-
formed at the Clinical Neurochemistry Laboratory at
Sahlgrenska University Hopsital, Mölndal, Sweden. CSF
cut-off for pathological level was < 530 pg/ml (Aβ42
+/−), ≥ 60 pg/ml (p-tau+/−), and > 350 pg/ml (t-tau
+/−) [31].
Statistical analyses
Analyses were performed by parametric or non-parametric
statistics as appropriate depending on the data distribution.
Data distribution was assessed by histogram, probability-
probability (P-P), and quantile-quantile (Q-Q) plots. As
CSF sTREM2 raw data were skewed, continuous data are
reported by median (interquartile range (IQR)) and group
differences analyzed by Mann-Whitney or Kruskal-Wallis
test. p values of group comparisons were obtained by
Mann-Whitney test, unless otherwise reported. The correl-
ation analyses are reported by Spearman’s rho correlation
coefficient (rs).
Multiple linear regression was used for analyses with
multiple predictor variables. For stepwise multiple linear
regression, predictors were included based on signifi-
cance in univariate analyses and biological grounds, in-
cluding predictors with highest assumed degree of
explained variability first. The data transformation by
the natural logarithm (ln) (ln(CSF sTREM2 ng/ml)
approximated a normal distribution and was therefore
applied for analyses requiring parametric tests (linear re-
gressions). Standardized residuals in linear regressions
met the criteria of normal distribution. In regression
analyses with delirium, no delirium was coded as 0 and
delirium as 1. In linear regressions with delirium onset;
no delirium was coded as 0, incident delirium as 1, and
prevalent delirium as 2.
All hypotheses were two-sided and the reported p
values are therefore two-tailed. The significance level
was set at p < 0.05. Statistical analyses were performed
by the Statistical Package for Social Sciences (SPSS, ver-
sions 24 and 25; IBM, Armonk, NY, USA). Graphical il-
lustrations were created with GraphPad Prism (version
7.04 Graph Pad Software, La Jolla, CA, USA).
Results
Increased CSF sTREM2 with delirium in hip fracture
patients without pre-existing dementia
The patients studied did or did not develop delirium dur-
ing hospitalization after a hip fracture requiring acute sur-
gery. Around half of the patients included were demented
before the accident, and a large proportion of those de-
mented patients developed delirium after the hip fracture
(≈ 80%; study setup in Fig. 1a). All the patients displayed
an advanced age irrespective of dementia diagnosis (me-
dian age 85 years). The gender distribution was similar be-
tween groups (Table 1). Gender did not influence the CSF
sTREM2 level and was therefore not included in the fur-
ther analyses (data not shown).
Initial analyses of the CSF sTREM2 level showed a
considerable intragroup variability, both among patients
with and without delirium, with no separation between
these two groups (p = 0.25, CSF sTREM2: 7.7(7.9) versus
7.4(5.4) ng/ml, n = 65, n = 54; Fig. 1b). Neuropathology
of several dementia disorders involves microglial activa-
tion, and the underlying pathogenic processes may be
different in delirium superimposed on dementia as com-
pared to delirium in the absence of pre-existing demen-
tia. Interestingly when stratifying patients according to
pre-fracture dementia, an increased CSF sTREM2 level
was only associated with delirium among those patients
who were not demented before the hip fracture (p =
0.046, CSF sTREM2: 11.1(11.0) versus 7.4(5.0) ng/ml, n
= 15, n = 44). In contrast, among patients with a pre-
existing dementia, the CSF sTREM2 level did not differ
between those patients who did or did not develop delir-
ium (p = 0.94, n = 50, n = 10; Fig. 1c and Table 1).
CSF sTREM2 in relation to onset of delirium in hip
fracture patients
During delirium, microglial reactivity may be transient and
CSF sTREM2 levels may therefore fluctuate in a manner
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not directly related to clinical symptoms. To investigate
possible changes in CSF sTREM2 with delirium progres-
sion, we stratified the delirium patients by onset of delirium
relative to time of surgery when CSF was sampled (see
Fig. 1a). Patients with pre-operational delirium were classi-
fied as having prevalent delirium, while those with post-op-
erational delirium were categorized as having incident
delirium. Among patients without pre-existing dementia,
the incident delirium group showed an increased CSF
sTREM2 level as compared to patients not developing delir-
ium (p = 0.02, CSF sTREM2: 11.6 (5.0) versus 7.4 (5.0) ng/
ml, n = 7, n = 44). The patients with prevalent delirium dis-
played a large variability in CSF sTREM2 and did not differ
statistically neither from the unaffected patient group nor
from the group having incident delirium (p = 0.46, p = 0.45,
n = 8, n = 44, n = 7). When likewise stratifying patients with
pre-existing dementia into subgroups of onset of delirium,
the CSF sTREM2 level did not differ between the three
groups (p= 0.62, Kruskal-Wallis test, Fig. 2 and Table 1).
CSF sTREM2 in relation to waiting time for surgery
among hip fracture patients
A peripheral insult, such as a hip fracture, may trigger a
central immune response [32]. The CSF sTREM2 level cor-
related positively to waiting time for surgery after hospital
admission (waiting time for surgery (h); rS = 0.23, p = 0.01,
Fig. 1 CSF sTREM2 in patients hospitalized by a hip fracture. a A fragment of the microglial receptor TREM2 and sTREM2, released after
ectodomain shedding, drains to the CSF. Sampling and time line of hip fracture patients admitted to the hospital where some of them
developed delirium. b CSF sTREM2 level did not discriminate patients not developing delirium from patients developing delirium during
hospitalization for an acute hip fracture surgery (p = 0.25, n = 54, n = 65). c Stratification and separate analyses of patients with and without pre-existing
dementia showed significantly higher CSF sTREM2 level in delirium of patients without pre-existing dementia (p = 0.046, n = 15, n = 44). Dementia
patients with and without delirium had a similar CSF sTREM2 level (p = 0.94, n = 10, n = 50). Two tailed p values were obtained by Mann-Whitney test,
while larger and smaller lines represent the median and interquartile range respectively. CSF: cerebrospinal fluid, sTREM2: soluble TREM2
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n = 119). The positive correlation in all patients was pre-
sumably due to a stronger positive relationship between
CSF sTREM2 and waiting time for surgery among patients
with pre-existing dementia, which remained when demen-
ted patients not developing delirium were excluded (rS =
0.39, p = 0.002, n = 60; rS = 0.40, p = 0.005, n = 49, Fig. 3 and
Table 2).
Having found CSF sTREM2 to relate positively to sur-
gery waiting time among patients with pre-existing de-
mentia, we were concerned that this masked an effect of
delirium on CSF TREM2 in our previous analyses of pa-
tients with pre-existing dementia. We adjusted for sur-
gery waiting time, but delirium did still not affect the
CSF TREM2 level in this group of demented patients
(multiple linear regression bivariate model; waiting
time for surgery (h): β1 = 0.007, p = 0.02, delirium: β2
= − 0.12, p = 0.60, n = 59, Table 3). The same analyses
of delirium patients with pre-existing dementia
sub-grouped relative to delirium onset (incident or
prevalent delirium) reiterated that surgery waiting
time, but not delirium onset, influenced the CSF
TREM2 level (data not shown).
CSF sTREM2 in relation to age among hip fracture
patients
The study group was of an advanced age (median of
85 years), and CSF sTREM2 did not relate to patient age
(rS = 0.09, p = 0.32, n = 120, Additional file 1: Figure S1).
Morbidity or comorbidity might have masked an effect of
aging on CSF sTREM2 that we observed in a cohort with a
wider age distribution [22]. However, CSF sTREM2 did
still not relate to age when restricting the analysis to the
patient group having neither pre-existing dementia nor de-
lirium (rS = 0.12, p = 0.43, n = 44; Additional file 1: Figure
S1A and Table 2). The four study groups of the hip frac-
ture cohort, patients with or without delirium and with or
without pre-existing dementia, were age-matched when
assessing median age. However, the patient group having
neither pre-existing dementia nor delirium had a greater
proportion of relatively young individuals than the other
groups. Neuroinflammation is a feature of aging, and we
wanted to ensure that the age distribution did not infer
with our analyses. We approached this by adjusting for age
and analyzing data with multiple linear regression models.
CSF sTREM2 remained significantly increased with delir-
ium in age-adjusted analyses of patients without dementia
(p < 0.05, ln(CSFsTREM2); univariate model: delirium β1
= 0.40, p = 0.01; with a bivariate model: delirium β1 = 0.35
p = 0.03; age β2 = 0.01, p = 0.22, n = 59). This finding reiter-
ated when reanalyzing the effect of incident delirium
among patients without dementia (ln(CSFsTREM2):
incident delirium β1 = 0.52, p = 0.01; a bivariate model: in-
cident delirium β1 = 0.47, p = 0.03; age β2 = 0.01, p = 0.26,
n = 51, Table 3).
Fig. 2 CSF sTREM2 in delirium separated by onset in patients with and without dementia. Delirium patients were separated by symptom onset
prior to or after hip fracture surgery (prevalent- and incident delirium respectively). Among patients without dementia, patients with delirium
after CSF sampling (incident delirium) displayed a significantly higher CSF sTREM2 level than patients without delirium (p = 0.02, n = 7, n = 44). CSF
sTREM2 in patients with delirium before CSF sampling (prevalent delirium) did not differ from neither those with incident delirium nor from patients
without delirium (p = 0.45 and p = 0.46, n = 7, n = 8, n = 44). Separating delirium patients with dementia by delirium onset before or after surgery did
not reveal any differences between patient groups. The p values are two-tailed and obtained by Mann-Whitney test, larger and smaller lines represent
the median and interquartile range respectively. CSF: cerebrospinal fluid, sTREM2: soluble TREM2
Henjum et al. Journal of Neuroinflammation          (2018) 15:304 Page 6 of 15
CSF sTREM2 in relation to amyloid-β metabolism and
plaque sequestration in hip fracture patients
In several reports, CSF sTREM2 level relates to CSF core
biomarkers of Alzheimer’s disease Aβ42, t-tau, and p-tau
[19, 21, 22]. We hypothesized observing such relations
in the present study, with the comorbidities delirium or
pre-existing dementia acting as possible confounders.
First the relations were analyzed in all patients, then pa-
tients were stratified by dementia status and finally by
delirium. After stratification by both factors, only two
patient groups, those neither having pre-existing demen-
tia nor delirium (n = 44) and those being afflicted by
both conditions simultaneously (n = 50) were of a suffi-
cient group size to merit further statistical analyses
(Table 1).
Reduced CSF Aβ42 is assumed to reflect parenchymal
Aβ sequestration by plaques in AD brain. CSF sTREM2
and CSF Aβ42 related positively in the entire hip frac-
ture cohort (rS = 0.22, p = 0.02, n = 117). When stratify-
ing study subjects by pre-existing dementia status, CSF
sTREM2 and CSF Aβ42 did not correlate in patients
without pre-existing dementia, not even after excluding
patients with delirium. In contrast, there was a strong
positive relation between CSF sTREM2 and CSF Aβ42 of
patients with pre-existing dementia which grew stronger
when demented patients without delirium were excluded
from the analysis (rS = 0.40, p = 0.002, n = 60; rS = 0.53, p
< 0.001, n = 50, Fig. 4 and Table 2).
How prone an Aβ peptide is to form amyloid fibrils and
be sequestered by a pre-existing Aβ deposit in the brain
Fig. 3 Time-dependent influence of waiting time for hip fracture surgery the CSF sTREM2. CSF was sampled immediately before surgery started.
a Among patients without dementia, there was no correlation between the CSF sTREM2 level and waiting time for surgery from hospital admission
(hours; waiting time for surgery). b In contrast, among dementia cases, the CSF sTREM2 level increased with time from hospital admission until surgery
with a positive correlation coefficient (rs). The correlations are calculated for all patients with or without pre-existing dementia respectively, but patients
with and without delirium are indicated by separate symbols. CSF: cerebrospinal fluid, sTREM2: soluble TREM2. rs: Spearman’s rho
Table 2 CSF sTREM2 Spearman’s Rho correlations in the hip fracture cohort
PATIENTS WITHOUT DEMENTIA PATIENTS WITH DEMENTIA
All No delirium Delirium All No delirium Delirium
N 59 44 15 61 (60) 10 50
Rho p Rho p Rho p Rho p Rho p Rho p
Age 0.21 0.12 0.12 0.43 0.23 0.40 0.00 0.98 0.16 0.66 -0.05 0.74
Time to surgery (hours) * 0.01 0.93 -0.03 0.83 0.06 0.84 0.39 0.002 0.43 0.21 0.40 0.005
CSF Biomarkers
N 57 44 13 60 9 50
Rho p Rho p Rho p Rho p Rho p Rho p
CSF Aβ42 (pg/ml) 0.11 0.40 0.20 0.18 0.31 0.30 0.40 0.002 0.02 0.97 0.53 <0.001
CSF Aβ38 (pg/ml) MSD 0.09 0.49 0.06 0.71 0.18 0.55 0.44 <0.001 0.40 0.29 0.45 0.001
CSF Aβ40 (pg/ml) MSD 0.14 0.32 0.12 0.44 0.23 0.45 0.48 <0.001 0.37 0.33 0.51 <0.001
CSF Aβ42 (pg/ml) MSD 0.09 0.52 0.24 0.12 -0.13 0.67 0.43 0.001 0.15 0.70 0.53 <0.001
CSF t-tau (pg/ml) 0.14 0.28 -0.04 0.82 0.20 0.51 0.46 <0.001 0.83 0.005 0.34 0.016
CSF p-tau (pg/ml) 0.12 0.38 -0.02 0.90 0.23 0.46 0.49 <0.001 0.77 0.016 0.37 0.008
Aβ42, amyloid beta 1–42; t-tau, total-tau; p-tau, phosphorylated tau; sTREM2, soluble triggering receptor expressed on myeloid cells
*Time to surgery, hours from hospital admission to surgery (onset of anesthesia) and CSF sampling
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heavily depends on the C-terminal extension. Indeed, in
clinical studies, only the level of hydrophobic Aβ peptides
extending to position 42 decrease in CSF when Aβ deposits
begin to form in brain [33]. Thus, an increased CSF level of
a C-terminal truncated Aβ peptide, e.g., CSF Aβ1–38 likely
reflect Aβ-monomer metabolism (production or catabol-
ism). Here, we related analyses of CSF Aβ38, Aβ40, and
Aβ42 MSD ELISA levels to CSF sTREM2. Our intent was
to distinguish if a putative relation between CSF sTREM2
and CSF Aβ42 was linked to Aβ-metabolism or Aβ-plaque
sequestration. The MSD analyses outcome was reminiscent
to the Innotest Aβ42 analysis, with CSF sTREM2 and CSF
Aβ relating positively to all three Aβ peptides (Aβ38 MSD,
Aβ40 MSD, and Aβ42 MSD). Upon stratification, the effect
was prominent among patients with pre-existing de-
mentia and even stronger when further excluding those
patients who did not develop delirium (Aβ38MSDrS =
0.45, p = 0.001; Aβ40MSDrS = 0.51, p < 0.001; Aβ42MSD
rS = 0.53, p < 0.001, n = 50; Additional file 1: Figure S2
and Table 2).
CSF sTREM2 in relation to CSF tau markers in hip fracture
patients
CSF t-tau and p-tau concentrations are thought to re-
flect altered tau metabolism that relates to neurodegen-
eration and tangle formation in AD [34]. CSF sTREM2
related positively to both CSF t-tau and p-tau in the en-
tire hip fracture patient cohort (rS = 0.32, p = 0.001 for
both, n = 117). Stratification by dementia status gave re-
sults reminiscent of the CSF Aβ-data, with strong corre-
lations to CSF sTREM2 restricted to patients with
pre-existing dementia (t-tau, rS = 0.46, p < 0.001; p-tau,
rS = 0.49, p < 0.001, n = 60). The relation between CSF-
TREM2 and tau markers remained but were weaker





Dementia Delirium adjusted by waiting time for surgery 59
Waiting time for surgery (β1) 0.007 0.02
Delirium (β2) -0.12 0.60
No dementia Delirium (at any time) 59
Delirium (univariate) 0.40 0.01
Delirium (adjusted) (β1) 0.35 0.03
Age (β2) 0.01 0.22
Delirium onset: incident delirium 51
Incident delirium (univariate) 0.52 0.01
Incident delirium (β1) 0.47 0.03
Age (β2) 0.01 0.26
Dementia AD pathological CSF-biomarkers, age and delirium 59
p-tau (β1) 0.01 <0.001
Aβ42 (β2) 0.002 0.002
Age (β3) 0.0001 0.91
Delirium (β4) - 0.03 0.86
No dementia AD pathological CSF-biomarkers, age and delirium 57
Delirium (β1) 0.47 0.02
p-tau (β2) 0.0000 0.97
Aβ42 (β3) 0.0000 0.16
Age (β4) 0.013 0.13
No dementia Incident (hip fracture) and medical delirium age adjusted 24
Incident delirium (univariate) 0.62 0.05
Incident delirium (β1) 0.27 0.48
Age (β2) 0.02 0.15
aLinear regression with the dependent variable ln (sTREM2ng/ml). Aβ42; amyloid beta 1-42, t-tau; total-tau; p-tau; phosphorylated tau, sTREM2; soluble triggering
receptor expressed on myeloid cells
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when restricting the analyses to demented patients who
also developed delirium (t-tau, rS = 0.34, p = 0.016, n = 50
and p-tau, rS = 0.37, p = 0.008, n = 50; Fig. 5, Table 2).
CSF sTREM2 and predictive ability of delirium, age, and
AD CSF-biomarker level
Only among patients with pre-existing dementia did
CSF sTREM2 relate positively to the three CSF AD core
biomarkers (Aβ42, t-tau, and p-tau). Here in a separate
examination, CSF Aβ42 and p-tau were included in mul-
tiple linear regressions to explore if AD core biomarkers
together better explained the variability of CSF sTREM2.
The biomarker CSF p-tau was chosen above t-tau since
it is more AD-specific [35] and since previous analyses
gave slightly higher correlation coefficients to CSF
sTREM2. Such analyses enabled us to examine if effects
of AD neuropathology, reflected by biomarkers CSF
Aβ42 and CSF p-tau, masked an effect of delirium on
CSF TREM2.
Again, the hip fracture patient cohort was stratified for
pre-existing dementia. Variables included were delirium,
age, CSF Aβ42, and CSF p-tau. In the patient group with
pre-existing dementia, the AD CSF biomarkers were in-
cluded as predictors before incorporating age and delir-
ium in the analysis. CSF p-tau explained most variability
as a sole predictor of CSF TREM2 level (R = 0.50). In-
cluding CSF Aβ42 as a second predictor increased the
explained CSF sTREM2 level variability (R = 0.61), while
age and delirium did not further increase predictive abil-
ity (ln(CSF sTREM2): CSF p-tau β1 = 0.01, p < 0.001;
CSF Aβ42 β2 = 0.002, p = 0.002; age β3 = 0.0001, p = 0.91;
delirium β4 = − 0.03, p = 0.86; n = 59). Irrespective of the
number of predictors included, the effect size (β) re-
mains essentially the same (Table 3).
The patient group without pre-existing dementia
was examined in the same manner with multiple lin-
ear regressions. Delirium was included as the initial
predictor before incorporating age and the AD core
CSF biomarkers Aβ42 and p-tau. Delirium was the
only significant predictor in this patient group (R =
0.34 as a single predictor). CSF AD core biomarkers
did not have a significant impact and their inclusion
and subsequent adjustment did not influence the ef-
fect size (β) of delirium (ln(CSF sTREM2: delirium
β1 = − 0.47, p = 0.02; CSF p-tau β2 = 0.000, p = 0.97;
CSF Aβ42 β3 = 0.000, p = 0.16; age β4 = 0.013, p = 0.13,
n = 57). This model suggest that patients without pre-
existing dementia, but afflicted by a hip fracture and
subsequent delirium would result in an increased CSF
TREM2 level (≈ 1.5 ng/ml). This applied to conditions
adjusted for interfering factors, age, or CSF biomarker
levels indicating AD neuropathology (Table 3).
CSF sTREM2 and ratios of tau and amyloid CSF
biomarkers
We then examined ratios of amyloid and tau CSF bio-
markers, which are more discriminative than a single
biomarker to the diagnosis and prognosis of AD [36,
37]. Biomarker ratios (t-tau/Aβ42 or p- tau/Aβ42) sep-
arated non-demented patients with or without delir-
ium (Additional file 1: Table S1), consistent with a
previous report [10]. There was no correlation be-
tween CSF sTREM2 and CSF t-tau/Aβ42 and p-tau/
Aβ42 among those with dementia or without dementia
(Additional file 1: Table S1 and Figure S3).
Fig. 4 Relation between the level of CSF biomarkers sTREM2 and Aβ42 in hip fracture patients. a Among patients without pre-existing dementia,
there was no correlation between sTREM2 and Aβ42 in CSF, but (b) a positive relation in patients with dementia as indicated by a significant and
positive correlation (rs). The correlations are calculated for all patients with or without dementia respectively, but patients with and without delirium
are indicated by separate symbols. The dotted lines show the pathological biomarker cut-off level (530 pg/ml). To present Figs. 4 and 5 in the same
manner, the x-axes in Fig. 4 are reversed because a low level indicates Aβ pathology. CSF: cerebrospinal fluid, Aβ42: amyloid beta 1–42, sTREM2:
soluble TREM2. rs: Spearman’s rho
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CSF sTREM2 level and AD neuropathology
AD is the major cause of dementia. To identify hip fracture
patients with pre-existing dementia likely due to AD, we
applied cut-off values for the CSF Aβ42 and CSF-tau [31].
Thus patients were stratified for having a CSF Aβ42-level
above or below AD cut-off (Aβ−/Aβ+) and likewise tau-
level (t-tau or p-tau) above or below AD cut-off (tau
+/tau-) [38]. Most patients with pre-existing dementia
were below CSF Aβ42 cut-off (≈ 90%), while fewer patients
were above CSF-tau cut-off (≈ 40%, Table 1).
Among patients neither having delirium nor pre-exist-
ing dementia, CSF sTREM2 level did not differ between
those who were above or below CSF-biomarker CSF
Aβ42 level cut-off for AD (p = 0.22, n = 26 n = 18).
Among patients without pre-existing dementia and a
CSF Aβ42 level below cut-off, CSF sTREM2 was higher
in those with subsequent delirium (n = 11) as compared
to unaffected subjects (n = 26; p = 0.048). The analyses
gave similar results as when all patients without pre-
existing dementia were included in the analyses (p =
0.046, Fig. 1c). Corresponding analyses for tau (t-tau or
p-tau positive) yielded essentially the same results (data
not shown). These analyses confirm multiple linear re-
gression analyses of CSF Aβ42 and CSF tau markers not
influencing the CSF sTREM2 level in patients without
pre-existing dementia.
CSF sTREM2 in patients with medical delirium
We also included a group of delirium patients having
delirium secondary to a medical condition with or with-
out pre-existing dementia (medical delirium, n = 26,
Table 1). There was a trend of a lower CSF sTREM2
level in patients with medical delirium as compared to
those with delirium after a hip fracture (p = 0.08; CSF
sTREM2 ng/ml: 6.1 (7.3) vs 7.7 (7.9), n = 26, n = 65,
Figs. 1b and 6).
Restricting the analyses only to patients without
pre-existing dementia, CSF sTREM2 was reduced in
Fig. 5 CSF levels of tau markers and sTREM2 in patients without or with pre-existing dementia. In CSF, there were no correlation between sTREM2 and
either t-tau or p-tau in patients without pre-existing dementia (a, c). In contrast, both CSF tau markers, t-tau, and p-tau, correlated positively to CSF
sTREM2 only in dementia patients (b, d) as indicated by significant and positive correlations (rs). The correlations were calculated for all patients with or
without pre-existing dementia respectively, while patients with and without delirium are indicated by separate symbols. The dotted lines
show pathological biomarker cut-off level (350 pg/ml and 60 pg/ml). CSF: cerebrospinal fluid, sTREM2: soluble TREM2, p-tau: phosphorylated181 -tau, t-
tau: total tau, rs: Spearman’s rho
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medical delirium as compared to patients with hip frac-
ture triggered delirium (p = 0.04; n = 17, n = 15, Figs. 1
and 6; Table 1). Restricting the hip fracture cohort delir-
ium patients to those with incident delirium CSF
sTREM2 was lower, and close to significant (p = 0.055; n
= 7, n = 17), but not when compared to those with
prevalent delirium (p = 0.18, n = 8, n = 17; Figs. 2 and 6).
Analyzing only those with pre-existing dementia, CSF
sTREM2 in patients with medical delirium did not sta-
tistically differ from hip fracture patients with delirium
(p = 0.56, n = 9, n = 50; Fig. 1c and 6 and Table 1), nor
when comparing to each subgroup.
CSF sTREM2 in medical delirium patients in relation to
age and gender
Like in the hip fracture cohort, we found CSF sTREM2
not related to age neither when analyzing all medical de-
lirium patients (rS = 0.23, p = 0.26, n = 26) nor when
restricting the analysis to patients without dementia (rS
= 0.41, p = 0.11, n = 17, Additional file 1: Figure S4). Pa-
tients admitted to the hospital with medical delirium
were younger with a greater age range (66(16) years,
Table 1) than the patients having a hip fracture accident.
When adjusting for age, the level of CSF sTREM2 was
not significantly higher in hip fracture triggered delirium
relative to medical delirium. However, the group size is
almost too small to allow statistical age adjustment with
several covariates, and the loss of significance from
univariate analyses may be explained by additional noise
from the added predictor (ln(CSFsTREM2) univariate
model; delirium: β1 = 0.62, p = 0.05, and with a bivariate
model and age included: delirium β1 = 0.27, p = 0.48, age
β2 = 0.02, p = 0.15, n = 24).
Discussion
This is the first study to report on CSF sTREM2 level in
delirium. Moreover, the study differs from previous in-
vestigations by analyzing CSF sTREM2 as a biomarker
in a dementia population of an advanced age. Although
we did not see an overall effect of delirium, analyzing
patients with and without pre-existing dementia separ-
ately revealed a clear differential effect on CSF sTREM2
and interrelations to other biomarkers in these two pop-
ulations. Delirium increased CSF sTREM2 only in pa-
tients without pre-existing dementia. TREM2 is a highly
microglial-specific receptor, and ectodomain shedding of
TREM2 releases sTREM2 that then presumably drains
to CSF [18]. The level of sTREM2 in the brain reflects
amyloid-induced microglial activation in transgenic mice
with aging as judged by PET imaging [39]. Patient studies
also suggest that microglial-derived CSF sTREM2 in-
creases with a general glial-mediated immune response,
e.g., a positive relation with the astroglial CSF-marker
YKL-40 [19]. We therefore argue that increased sTREM2
in delirium without pre-existing dementia is due to central
microglial activation. We speculate that CSF sTREM2 in-
creases only in delirium patients without dementia be-
cause the pathogenic process is less complex and the
inflammatory process will more clearly stand out in this
patient group.
Increased CSF sTREM2 with delirium triggered by hip
fracture was most prominent in incident delirium, i.e., in
CSF sampled before the delirium syndrome was evident
in non-demented patients. Medical delirium patients all
suffered encephalopathy at the time of CSF sampling.
Interestingly, patients with medically induced delirium
displayed lower CSF sTREM2 relative to patients with
hip fracture-triggered delirium. This effect was close to
significant when compared to incident delirium patients
alone. Thus, stratification of delirium-afflicted patients
suggests that CSF sTREM2 increases transiently prior to
delirium onset, but then declines. An early but transient
glial response in delirium is supported by increased
levels of other CSF biomarkers of immune responses in
incident delirium, such as neopterin [40] and astroglia-
derived S-100β [41]. Thus, CSF sTREM2 is a promising
biomarker of microglial activation that is presumably
more usable to detect transient responses, which is con-
sistent with TREM2 having a rapid cell surface turnover
(< 1 h) [42]. Longitudinal studies and continuous CSF
sampling of delirium patients could confirm or refute
Fig. 6 CSF sTREM2 level in patients with medical delirium. There
was a tendency of a reduced CSF sTREM2 level in patients who
presented with or developed delirium secondary to a medical
condition compared to patients with delirium following a hip
fracture (p = 0.08; n = 26, n = 65). Restricting the analyses to only
patients without pre-existing dementia, hip fracture-triggered
delirium patients displayed a higher CSF sTREM2 level than the
medical delirium patients (p = 0.04, n = 15, n = 17). CSF: cerebrospinal
fluid, sTREM2: soluble TREM2
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this hypothesis, although it might be ethical challenging
to conduct such a study with fragile patients.
In contrast, delirium did not alter the CSF sTREM2
level in patients with pre-existing dementia nor did de-
mentia by itself affect CSF sTREM2. CSF sTREM2 is re-
ported increased in younger and CSF biomarker-selected
AD patients (mean ≈ 65–70 years) (e.g., [19, 20]). We
speculate that superimposed dementia with Aβ deposits
and tau inclusions continuously stimulating microglial
activation diminish the effect of delirium on microglial
response and sTREM2 release. Such proteinaceous
neuropathology might also lead to an increased protein
turnover preventing a raised interstitial sTREM2 level in
demented patients. Importantly, as compared to many
other CSF-dementia studies, the patients examined by
us were markedly older (median ≈ 85 years) and not
biomarker-selected and their dementia pathogenesis was
likely more heterogeneous [43, 44]. Thus, comorbidities
and advanced age could have diluted the direct link from
AD neuropathology to enhanced sTREM2 release and
CSF sTREM2.
The initial hip fracture trauma presumably activated
peripheral immune responses in the patients. The neu-
roinflammatory hypothesis of delirium suggests that
brain dysfunctions and clinical presentation are second-
ary to peripheral immune activation [4]. Dementia pa-
tients displaying increased CSF sTREM2 with waiting
time for acute hip fracture surgery is consistent with this
theory. That this only was evident among dementia pa-
tients also support the concept of primed more easily ac-
tivated microglia in neurodegenerative disease compared
to a healthy brain [45, 46].
Exploring relations between CSF biomarkers may
provide better pathogenic understanding by hinting
to simultaneously ongoing processes in the brain.
CSF Aβ and t-tau/p-tau markers related positively to
CSF sTREM2 only in dementia patients with delir-
ium, possibly suggesting somewhat distinct biological
processes of delirium with or without pre-existing de-
mentia. CSF sTREM2 related positively to CSF Aβ42
in the demented patients, essentially all of which
were below the CSF Aβ42 cut-off level. Clinical data
suggest that Aβ42 is sequestered by senile plaques,
long before symptom onset leading to a pronounced
drop in CSF Aβ42. This low CSF Aβ42 level is then
stable in the individual patient [47, 48]. Thus, a posi-
tive relation between CSF Aβ42 and CSF sTREM2 in
demented patients does presumably not relate to the
extent of amyloid deposition. Instead, it is more
likely to reflect shared protein synthesis and metabol-
ism of Aβ precursor protein (AβPP) and TREM2, an
idea which is consistent with our findings of positive
relations also to the shorter and far less plaque-
sequestered C-terminal truncated peptides Aβ38 and
Aβ40 [49]. AβPP and TREM2 share common features
of ectodomain shedding by ADAMs α-secretase and
subsequent γ-secretase cleavage [18, 50–52], and al-
though they are released by different cell types, one
can speculate whether both play a role to similar
physiological functions that involve neuronal-glial
communication.
An expanding literature links Aβ production to neur-
onal and synaptic activity and biological rhythms, e.g.,
sleep-wakefulness [53, 54]. We speculate that delirium
in dementia patients triggers neuronal network activa-
tion with concomitant enhanced release of Aβ peptides,
t-tau/p-tau, and sTREM2; all reflected by a transiently
increased CSF level. Interestingly, a recent study dem-
onstrated with isotope labeling kinetics that increased
CSF-tau in early AD reflects neuronal tau-synthesis and
positively correlates with amyloid-PET, but not
tau-PET [55]. Thus, CSF- t-tau/p-tau levels might also
reflect neuronal activity associated with amyloid, and
not simply axonal damage and tauopathy as previously
thought. There are reports of neuronal network distur-
bances in Alzheimer’s disease as well as delirium [56,
57]. Thus, our observations of positive CSF-biomarker
associations only in demented patients might be due to
the susceptibility of frail brains to neuronal network
dysfunctions.
CSF sTREM2 and tau markers interrelated in several
studies of AD cohorts, yet in different subpopulations
[19, 20, 58]. CSF sTREM2 clearly increased in a cohort
of suspected non-amyloid pathology (SNAP) patients
having cognitive dysfunctions and only positive CSF-tau
biomarkers indicating that elevated CSF sTREM2 can
occur independent of amyloid pathology [58]. Indeed,
inclusion of p-tau in linear regression analyses showed
that p-tau was the best sole predictor. Including CSF
Aβ42 as a second predictor better explained CSF
sTREM2 variability in the dementia group, while incorp-
orating variables age and delirium did not. Thus, in de-
mentia patients, the existing neuropathology seemed to
exceed any delirium effects again suggesting pathogenic
differences of delirium with and without pre-existing
dementia.
With aging, dementia does not well relate to Aβ path-
ology and tauopathy, presumably because of increased
importance of cerebrovascular comorbidity [59]. The
high median age and limited age distribution of the
study cohort likely explain why CSF sTREM2 did not re-
late to age. There might also be a ceiling effect of CSF
sTREM2 with aging, which would be worth further
studying. CSF sTREM2 increases with aging in several
studies that involved younger patient populations [20–
22]. Indeed, there was a tendency of a positive correl-
ation with aging among patients with medical delirium
that included younger individuals.
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Conclusion
The present biomarker analyses hint at the biological
processes of delirium being dependent on pre-existing
dementia with selectively increased CSF sTREM2 in de-
lirium only in the absence of dementia. These prelimin-
ary findings need replication in independent patient
cohorts and assays. Statistical power is a study limitation
with small cohorts after stratification. CSF sampling
aged frail patients in a confused state is practically and
ethically difficult and the CSF material used is unique in
size and composition. As judged by mutant TREM2-var-
iants, both increased and decreased shedding can reflect
reduced cell surface TREM2 and impaired gene function
[51, 60]. Increased sTREM2 likely represents microglial
activation but whether such central immune activation
is beneficial or detrimental to brain functions remains
unclear. Increased CSF sTREM2 prior to delirium could
possibly serve as a delirium risk indicator, albeit not
alone. An inflammatory CSF biomarker panel that in-
cludes sTREM2 might aid identification of at-risk pa-
tients with special care requirements in the post-
operative care unit.
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